IL17RA (Interleukin 17 Receptor A)

In vivo experiments confirmed that low-dose GCP intervention significantly reduced intestinal hemorrhage and edema, decreased parasite loads in intestinal and cerebral tissues of infected mice, and suppressed protein expression of IL-17RA, TNF-α, p-C/EBPβ and p-NF-κB in intestinal tissues. These findings demonstrate that GCP mitigates NC-induced IEC injury by modulating intestinal immune homeostasis through the C/EBPβ/IL-17/TNF signaling pathway, thus establishing a theoretical basis for developing natural therapeutics against pathogen-induced gut damage.

Collectively, these findings demonstrate that E. cava-derived phlorotannins exert anti-metastatic effects through dual regulation of IL-17RA/Act1 and ERK1/2 signaling pathways, offering mechanistic insight into their therapeutic potential against inflammation-driven malignancies.

The patient was refractory to corticosteroids, dapsone, and roflumilast, and developed recurrent Gram-negative infections. Brodalumab may offer a safe and effective treatment option in refractory pyoderma gangrenosum, particularly in patients with contraindications to conventional therapies. This case supports further evaluation of IL-17 pathway inhibition in neutrophilic dermatoses.

DOEA alleviates LPS-induced acute lung injury and cellular inflammatory responses by inhibiting the IL-17 signaling pathway.

In conclusion, rs9791323 in IL17A may contribute to disease susceptibility, while other IL17-related SNPs appear to influence specific clinical features. These findings highlight the potential role of IL17 gene variants in both the pathogenesis and phenotypic variability of autoimmune-associated orbital inflammation.

To investigate IL-17RA's functional role, CRC cells with stable IL-17RA overexpression were analyzed for changes in CSC marker expression, sphere formation, and 5-fluorouracil (5-FU) resistance...Specific inhibitors of IL-17RA signaling, such as the STAT3 inhibitor Stattic, reduced the expression of CD133, LGR5, ALDHA1, SOX2 and c-MYC, as well as tumor sphere formation in SW620 cells. These findings elucidate a novel IL-17RA-STAT3 axis that regulates CSC properties in CRC and highlight IL-17RA as a promising prognostic biomarker and therapeutic target for CRC treatment.

In conclusion, ALKBH5 promotes GC angiogenesis primarily through its m6A demethylase activity on targets such as lncRNA PVT1, which regulates VEGFA expression by modulating IL17RA/STAT3 signaling axis. ALKBH5 may serve as a promising biomarker and therapeutic target in GC.

In this study, we developed a new mouse model to understand the B cell-intrinsic role of IL-17RA signaling in gammaherpesvirus infection. Previous studies have shown that IL-17RA signaling is proviral in the context of gammaherpesvirus infection, and this study found that while B cell-intrinsic IL-17RA signaling is not the sole factor behind the systemic proviral role of IL-17RA signaling, it plays an important role in the virus-driven germinal center response, the expansion of B-1 B cells, and the establishment of chronic gammaherpesvirus infection.

Prolonged NHT enhances IL-17 A/IL-17RC-mediated inflammation in prostate cancer, potentially promoting tumor progression through STAT3 activation. Targeting the IL-17 A/STAT3 axis may offer therapeutic potential for advanced prostate cancer, although further validation is required before NHT can be incorporated into clinical guidelines.

GFL capsule exerts a protective effect against ALD in mice and hepatocytes, potentially through the inhibition of inflammation, oxidative stress and apoptosis. This study provides a solid theoretical foundation for the potential application of GFL capsule in the prevention and clinical management of ALD.

Studies evaluating AEs of interest for brodalumab showed no causal link to suicide and no increase in risk of cardiac events or serious infection compared with other biologics. Together, these studies support a consistent safety profile of brodalumab in real-world use.

From a previous phase 2 neoadjuvant immunotherapy window-of-opportunity study, we present the single-cell RNA and T cell receptor (TCR) sequencing analysis of 57 pre- and post-treatment tumor biopsies from head and neck cancer patients treated with durvalumab (anti-PD-L1) alone or with tremelimumab (anti-CTLA-4), identifying key cellular and molecular predictors of immune checkpoint inhibitor (ICI) response. The balance of Tpex1 and Tpex2 associates with ICI response across multiple cancers, offering insights into sustaining response. This study was registered at ClinicalTrials.gov (NCT03737968).